Alexandria Real Estate Equities (ARE) Stock Price & How to Invest

Alexandria Real Estate Equities is a real estate investment trust that pioneered the life-science real estate niche, building and operating collaborative lab and office campuses in top research clusters such as Boston/Cambridge, San Francisco, San Diego, Seattle, Maryland, and the Research Triangle. Its tenants are biotech firms, large pharmaceutical companies, medical-device makers, academic and government research institutions, and venture-backed startups, which lease specialized lab space that is expensive to build and hard to replicate. As a REIT, Alexandria distributes most of its taxable income as dividends and earns returns through rent, development of new campuses, and its strategic venture investments in the life-science ecosystem.

The investment picture in 2026 is defined by a tough operating backdrop. A slowdown in biotech funding and a wave of new lab supply has pushed occupancy down and pressured leasing, with Alexandria reporting an unusually weak first quarter that included no public-biotech lease signings. Management has responded by focusing on its highest-quality mega-campuses, selling non-core assets, and reaffirming full-year funds-from-operations (FFO) guidance. The stock trades at a low multiple of FFO with a mid-single-digit dividend yield, so the debate centers on whether the life-science leasing cycle recovers before vacancy and debt weigh further on cash flow.

The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. Rising vacancy, tenant credit stress among cash-burning biotechs, and mark-to-market rent risk could pressure FFO if the cycle does not recover. As a capital-intensive REIT, Alexandria carries meaningful debt, so higher-for-longer interest rates raise refinancing and development costs. Concentration in a single property type means a prolonged life-science downturn would hit it harder than a diversified landlord. Any dividend adjustment or further asset sales at depressed prices would also weigh on sentiment.

14 analysts publish price targets on ARE, averaging $53.00 against a $51.63 price as of September 2026, or +2.7%. The published targets run from $47.00 to $60.00, a narrow spread, and the ratings split 2 buy, 12 hold, 2 sell. Over the last six months there have been 6 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ARE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alexandria Real Estate Equities. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Mega-campus concentration. Alexandria is concentrating capital in large, amenity-rich campuses in the deepest research clusters, betting that top-tier tenants consolidate into the best locations. The most optimistic published target, $60.00, assumes this works close to its best case.

The case against. The near-term risk is a weak leasing environment: occupancy fell to roughly 87.7% in early 2026 amid biotech funding pressure, known lease expirations, and new lab supply, and the first quarter saw no public-biotech lease signings for the first time in company history. The most pessimistic target, $47.00, is roughly what ARE is worth if this bites instead.

Read the full bull and bear case on ARE, including what would have to change to break either one. Walnut is not an investment adviser.

No. Alexandria Real Estate Equities (ARE) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alexandria Real Estate Equities's investor relations page or your broker.

• Revenue (TTM): ~$2.7B
• Q1 2026 revenue: ~$671M
• FFO per share (2026 guidance midpoint): ~$6.40
• Q1 2026 adjusted FFO per share: ~$1.73
• Price / FFO: ~8x
• Market cap: ~$8.6B

For a REIT like Alexandria, FFO is the key earnings measure rather than GAAP EPS or P/E, because it adds back large non-cash property depreciation. At a high-single-digit multiple of guided 2026 FFO, ARE trades well below its historical range, reflecting market concern about occupancy and the life-science leasing cycle. The low multiple pairs with a mid-single-digit dividend yield.

Other names that sit close to ARE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ARE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ARE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ARE is a specialized life-science landlord trading at a depressed valuation and high yield while it works through soft biotech leasing and elevated vacancy.

Whether ARE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARE a buy or a sell?, and where the stock could go from here in the ARE stock forecast.

For income investors, whether ARE pays a dividend and how the payout looks is covered in does ARE pay a dividend? And to weigh ARE against a peer, read the full side-by-side comparisons: ARE vs VTR and ARE vs WELL.